stock-detail (ADXS)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

Adjuvant Chemotherapy Improves Overall Survival in Patients with Stage IB Non-Small Cell Lung Cancer

6/14/2016 07:02 am

(IASLC) June 13, 2016 - The use of adjuvant chemotherapy in early-stage non-small cell lung cancer (NSCLC) patients improves overall survival (OS) and 5-year OS in patients with tumor sizes ranging from 3 - 7 cm.

Colorectal Cancer Screening: Not All It's Cracked Up to Be?

4/28/2016 11:05 am

(Medscape Medical News) Apr 27, 2016 - "Unambiguous good news" — that's what the trends are in colorectal cancer incidence and mortality for adults 50 years and older in the United States, according to a pair of experts.

VolitionRx Announces Study Results Showing NuQ® Blood Test Detects Prostate Cancer Early with Significantly Higher Accuracy than PSA Test

4/20/2016 12:01 pm

(Yahoo! Finance) Apr 20, 2016 - VolitionRx Limited today announced that a single NuQ® biomarker assay detected 71% of early stage I prostate cancer cases at 93% specificity.

ELCC 2016 News: Comprehensive Molecular Profiling Shows Disparity Between Primary NSCLC Tumours and Metastases

4/15/2016 11:00 am

(ESMO) Apr 15, 2016 - Important differences of up to 47% in the expression rates of biomarkers between the primary tumour and metastatic sites were detected using comprehensive molecular profiling of non-small-cell lung cancer (NSCLC) samples.

New Law Allows Donation Of Unused Cancer Drugs

4/5/2016 11:02 am

(WLBZ-TV [NBC], Ch. 2 [Bangor, ME]/KING) Apr 5, 1016 - A new law will allow cancer patients in Washington state to donate their unused cancer drugs that have not been tampered with to people in need who may be underinsured or uninsured.

J&J Psoriasis Drug Stelara Eases Crohn's Disease in Second Trial

3/18/2016 10:02 am

(Reuters) Mar 18, 2016 - Johnson & Johnson's Stelara psoriasis drug has shown effectiveness against Crohn's disease in a second late-stage trial, the company said on Friday, bolstering prospects of its approval for the additional use.

CAR Trials Drive Leukemia and Lymphoma Treatment in New Direction

2/24/2016 11:05 am

(UC San Diego Health) Feb 23, 2016 - Researchers at UC San Diego Moores Cancer Center have launched three clinical trials to test the safety and efficacy of a novel cellular-immunotherapy that uses modified T cells – one of the immune system’s primary weapons – to treat three different types of blood cancer that often defy existing therapies.

Canadian Experts Say 'No' To Colonoscopy For Colon Cancer Screening

2/23/2016 11:05 am

(Reuters Health) Feb 22, 2016 - The Canadian Task Force on Preventive Health care recommends that colonoscopy should not be used to screen adults for colon cancer. Instead, they suggest testing for microscopic amounts of blood in the stool.

FDA Expands Use of Bristol Myers' Cancer Drug Yervoy

10/29/2015 11:05 am

(Reuters) Oct 28, 2015 - The U.S. Food and Drug Administration expanded the use of Bristol-Myers Squibb Co's skin cancer drug, Yervoy, as an additional therapy for patients with late-stage melanoma.

UnitedHealthcare Expands Effort to Rein in Rising Costs of Cancer Treatment

10/29/2015 11:05 am

(KHN) Oct 29, 2015 - UnitedHealthcare said Thursday it will expand its high-profile test of whether bundled payments for chemotherapy can help slow rising cancer treatment costs, part of a growing effort by insurers to find new ways to pay for care.

Coming: Prostate Cancer Treatment Guided by Biomarkers

10/29/2015 11:05 am

(Medscape Medical News) Oct 28, 2015 - In a phase 2 study, men with metastatic castration-resistant prostate cancer whose tumors harbored certain DNA-repair defects were much more likely to respond to the oral PARP (poly [ADP-ribose] polymerase) inhibitor olaparib (Lynparza, AstraZeneca Pharmaceuticals LP) than their peers whose tumors did not have these mutations.

A Grim Breast Cancer Milestone for Black Women

10/29/2015 11:05 am

(New York Times/Well blog) Oct 29, 2015 - For the first time, the incidence of breast cancer among black women is equal to that of white women, according to a sweeping new report from the American Cancer Society.

MEK Inhibitor Falls Flat in Pretreated Multiple Myeloma

10/29/2015 11:05 am

(MedPage Today) Oct 28, 2015 - The MEK inhibitor selumetinib (AZD6244) proved tolerable, but only minimally active as a single agent in heavily pretreated patients with relapsed or refractory multiple myeloma, according to findings from a six-center nonrandomized phase II trial.

Retroviral RNA May Play a Part in Liver Cancer

10/29/2015 11:05 am

(RIKEN [Japan]) Oct 29, 2015 - An international group led by RIKEN in Japan and INSERM in France have found that retroviral long-terminal-repeat (LTR) promoters—a type of repetitive element that are widely distributed in the human genome—are highly activated in hepatocellular carcinomas, the most common type of liver cancer.

Landmark Clinical Trial Shows Gene-Targeted Drug Can Treat Prostate Cancer

10/29/2015 06:03 am

(ICR [UK]) Oct 28, 2015 - A pioneering drug developed to treat women with inherited cancers can also benefit men with advanced prostate cancer, a major new clinical trial concludes.

Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for Yervoy (ipilimumab) as Adjuvant Treatment for Fully Resected Stage III Melanoma

10/29/2015 06:03 am

(MarketWatch) Oct 28, 2015 - First company to demonstrate the potential of an immune checkpoint inhibitor in the adjuvant treatment for these patients.

FDA Approves Yervoy To Reduce The Risk Of Melanoma Returning After Surgery

10/28/2015 04:03 pm

( Oct 28, 2015 - Today the U.S. Food and Drug Administration expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma, to lower the risk that the melanoma will return following surgery.

Astellas Inititaties Phase 3 Registration Trial of gilteritinib (ASP2215) in Relapsed or Refractory Acute Myeloid Leukemia Patients

10/28/2015 12:02 pm

(Astellas) Oct 28, 2015 - Astellas Pharma Inc. today announced dosing of the first patient in a randomized Phase 3 registration trial of gilteritinib (ASP2215) versus salvage chemotherapy in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The primary endpoint of the trial is overall survival (OS).

FDA Issues Complaints Against Bloodwork Biotech Firm Theranos

10/28/2015 12:00 pm

(USA Today) Oct 28, 2015 - Pressure on Silicon Valley biotech startup Theranos increased Tuesday with the Food and Drug Administration's release of complaints against the bloodwork company based on facility inspections earlier this summer.

Death From Heart Disease, Cancer And Other Big Causes Less Premature

10/28/2015 12:00 pm

(CNN) Oct 27, 2015 - The researchers found that the overall death rate has dropped sharply (42.9%) over the last four decades.

Medicare Cut for Physicians Helps Balance New Budget Deal

10/28/2015 12:00 pm

(Medscape Medical News) Oct 28, 2015 - To help offset an $80 billion spending increase, the bipartisan bill would extend a 2% sequestration cut of Medicare payment rates into fiscal 2025.

E-Cigarettes Appeal to Smokers Who Are Trying to Quit, Study Says

10/28/2015 12:00 pm

(Wall Street Journal) Oct 28, 2015 - A federal study on U.S. e-cigarette use among adults shows the devices appeal to current and former smokers trying to kick their cigarette habit.

What’s Got Americans Worried? Drug Costs

10/28/2015 11:05 am

(KHN Morning Briefing) Oct 28, 2015 - A new poll says the public's top health care concern is how much prescription drugs will cost them. Most Americans also believe the FDA should review drug ads before they air.

Increased Radiation Dose Offers No Survival Benefit for Patients with Low-Risk Prostate Cancer, Penn Study Finds

7/16/2015 11:03 am

(Penn Medicine) July 16, 2015 - Increased radiation dose is associated with higher survival rates in men with medium- and high-risk prostate cancer, but not men with low-risk prostate cancer, according to a new study from Penn Medicine published this week in JAMA Oncology.

Viewpoint: Refining Lung Cancer Staging in the Molecular Oncology Era

5/20/2015 11:05 am

(Medscape Oncology) May 19, 2015 - Dr. Jack West comments on a very provocative proof of principle demonstrating the effect next-generation sequencing may have on tumor staging.